Azafaros

Executive Summary

Azafaros is a Netherlands-based biotech company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting glycosphingolipid metabolism for central nervous system disorders. Supported by Dutch and Swiss investors, the company is focused on addressing rare lysosomal storage diseases and other neurodegenerative conditions. Founded in 2018, Azafaros is currently in the pre-clinical stage, advancing its lead candidate through IND-enabling studies. The unique mechanism of nizubaglustat, which combines substrate reduction and enzyme enhancement, holds promise for diseases with high unmet medical need, such as Gaucher disease and Parkinson's disease. With a strong scientific foundation and experienced team, Azafaros is poised to enter the clinic in the near term.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA Filing for Nizubaglustat70% success
• Q1 2027Initiation of Phase 1 Clinical Trial60% success
• Q2 2026Preclinical Efficacy Data Presentation at Major Conference80% success